Nanjing Well Pharmaceutical Group Co (SHSE:603351) LT-Debt-to-Total-Asset : 0.03 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Nanjing Well Pharmaceutical Group Co LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Nanjing Well Pharmaceutical Group Co's long-term debt to total assests ratio for the quarter that ended in Sep. 2024 was 0.03.

Nanjing Well Pharmaceutical Group Co's long-term debt to total assets ratio declined from Sep. 2023 (0.05) to Sep. 2024 (0.03). It may suggest that Nanjing Well Pharmaceutical Group Co is progressively becoming less dependent on debt to grow their business.

Nanjing Well Pharmaceutical Group Co LT-Debt-to-Total-Asset Historical Data

The historical data trend for Nanjing Well Pharmaceutical Group Co's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing Well Pharmaceutical Group Co LT-Debt-to-Total-Asset Chart

Nanjing Well Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.03

0.05

Nanjing Well Pharmaceutical Group Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.05	0.05	0.05	0.03	0.03

Nanjing Well Pharmaceutical Group Co LT-Debt-to-Total-Asset Calculation

Nanjing Well Pharmaceutical Group Co's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	104.064	/	2278.903
	=	0.05

Nanjing Well Pharmaceutical Group Co's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2024 is calculated as

LT Debt to Total Assets (Q: Sep. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2024 )	/	Total Assets (Q: Sep. 2024 )
	=	59.574	/	2279.437
	=	0.03

Nanjing Well Pharmaceutical Group Co (SHSE:603351) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Nanjing Well Pharmaceutical Group Co LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Nanjing Well Pharmaceutical Group Co's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing Well Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing Well Pharmaceutical Group Co Ltd (SHSE:603351) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

No. 99, Changfeng Hexi Road, Nanjing Chemical Industry Park, Jiangsu Province, Nanjing, CHN, 210000

Website

http://www.well-js.com

Nanjing Well Pharmaceutical Group Co Ltd is engaged in research and development, production and sales of pharmaceutical auxiliary materials and synthetic lubricating base oil and other products. The company uses a variety of pharmaceutical dosage forms such as injection, oral administration and external use to guarantee the molding, effectiveness, stability and safety of pharmaceutical dosage forms.

Executives

Zou Jian Guo	senior management
Wang Fu Qiu	Directors, senior managers
Wu Rong Wen	Supervisors

Nanjing Well Pharmaceutical Group Co Headlines

No Headlines